The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia. A Watertown biotech is ...

The obstetrician performed an ultrasound to ensure vertex/vertex delivery and requested that the patient labor in bed with continuous electronic fetal monitoring. She was assisted by husband ...

Vertex teamed up with Moderna in 2020 to identify and develop lipid nanoparticles (LNPs) and mRNAs for the delivery of gene-editing therapies to treat CF. In December 2022, the FDA cleared an ...

announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel and proprietary LNP delivery solutions to enhance Vertex’s efforts in ...

“We are excited to collaborate with [Vertex] to develop in vivo therapies that leverage our proprietary technologies to achieve unprecedented delivery to [hematopoietic stem cell]s," said Amit ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...